Images List Premium Download Classic

Antagonist

Antagonist-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Methods for personalizing patient cancer therapy with an mdm2 antagonist
Hoffmann-la Roche Inc.
August 10, 2017 - N°20170227544

The present application discloses a method to predict responsiveness of a patient, with cancer, to treatment with an mdm2 antagonist of formulae i, ii and iii as disclosed herein, said method comprising a multivariate analysis comprising detecting relative amounts of certain mdm2 protein expressing cells and, optionally additional co-variates selected from a gene signature as disclosed herein, p53 mutation status, ...
Predicting response to a vegf antagonist
Genentech, Inc.
August 10, 2017 - N°20170226198

The invention describes the use of high cd31 and/or tumor vegfa as selection criteria for determining patient benefit or responsiveness to a vegf antagonist, such as bevacizumab. The present invention also describes the use of high cd31 and/or tumor vegfa as a selection criterion for treating cancer patients, such as ovarian cancer patients, who are undergoing a chemotherapy ...
Selective inhibitors of constitutive androstane receptor
St. Jude Children's Research Hospital
August 10, 2017 - N°20170226115

The compounds of the invention are antagonists of car, with specificity for car over other proteins including pxr. The disclosed compounds are useful in treating or controlling cell proliferative disorders, in particular oncological disorders, such as cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting ...
Antagonist Patent Pack
Download 805+ patent application PDFs
Antagonist Patent Applications
Download 805+ Antagonist-related PDFs
For professional research & prior art discovery
inventor
  • 805+ full patent PDF documents of Antagonist-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
St. Jude Children's Research Hospital
August 10, 2017 - N°20170226082

Or a pharmaceutically acceptable salt thereof. Such compounds possess both muscarinic receptor antagonist and β2 adrenergic receptor agonist activities. The invention also relates to pharmaceutical compositions comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compounds as bronchodilating agents to treat pulmonary disorders.
Compositions for controlling plant parasitic nematodes and methods for using same
St. Jude Children's Research Hospital
August 10, 2017 - N°20170226024

Aspects of the invention include compositions for controlling plant parasitic nematodes. Compositions according to certain embodiments include a carbon skeleton energy compound, a chelating agent, macronutrients, micronutrients, an ionophore, exotic micronutrients and a plant parasitic nematode antagonist. Methods for using the compositions of the invention to control plant parasitic nematodes and kits having one or more compositions for controlling plant ...
Stable preservative free ophthalmic formulations of opioid antagonists
Imuneks Farma Ilac Sanayi Ve Ticaret Anonim Sirket
August 10, 2017 - N°20170224827

The present application is directed to stable preservative free ophthalmic formulations of opioid antagonists and use thereof in the treatment of retinal degenerative diseases.
Antagonist Patent Pack
Download 805+ patent application PDFs
Antagonist Patent Applications
Download 805+ Antagonist-related PDFs
For professional research & prior art discovery
inventor
  • 805+ full patent PDF documents of Antagonist-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods for treating cancer using inos-inhibitory compositions
The Methodist Hospital
August 10, 2017 - N°20170224814

Disclosed are methods for treating one or more mammalian cancers, and in particular, methods for treating human melanoma, or a head or neck cancer, that employ therapeutically-effective amounts of one or more inos pathway-inhibitory compounds, either alone, or in combination with one or more selected antihypertensive agents (including, for example, calcium channel antagonists), alone, or further in combination with one ...
Leukotoxin e/d as a new anti-inflammatory agent and microbicide
New York University
August 10, 2017 - N°20170224768

The present invention relates to methods for preventing or treating human immunodeficiency virus (hiv) infection, inflammatory conditions, and graft-versus-host-disease (gvhd) in a subject. Therapeutic compositions of the present invention comprise leukocidin e (luke) and/or d proteins or polypeptides. The invention further relates to methods of treating staphylococcus aureus infection by administering a composition comprising a ccr5 antagonist or any ...
Use of cxcr2 antagonists for the prevention and/or treatment of chemotherapy induced peripheral neuropathy (...
Glaxosmithkline Intellectual Property Development Limited
August 10, 2017 - N°20170224679

The invention relates to the use of a cxcr2 antagonist for the prevention and/or treatment of chemotherapy induced peripheral neuropathy (cipn).
Selective high affinity alfa3beta4 nicotinic acetylcholine receptor antagonists
Astraea Therapeutics
August 10, 2017 - N°20170224665

Provided herein are novel and selective high affinity α3β4 nicotinic acetycholine receptor ligands and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, drug addiction or pain using the compounds and compositions disclosed herein. In still other embodiments, provided herein are ...
Methods for the treatment of tinnitus induced by cochlear excitotoxicity
Auris Medical Ag
August 10, 2017 - N°20170224638

The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an nmda receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may ...
Antifungal paenibacillus strains, fusaricidin-type compounds, and their use
Basf Se
August 10, 2017 - N°20170223968

The present invention relates to novel isolated bacterial strains, which are members of the genus paenibacillus, originally isolated from soil and showing antagonistic activity against a broad range of pathogens and being capable of producing antimicrobial metabolites. It was found that the strains lu16774 and lu17007 belong to a novel subspecies named paenibacillus polymyxa ssp. Plantarum while the strain lu17015 ...
An antagonistic pd-1 aptamer and its applications in cancer therapy related applications
National Taiwan University
August 03, 2017 - N°20170218369

Aptamers that bind to and antagonize pd-1 and uses thereof in promoting t cell proliferation, treating cancer or infectious diseases such as hiv infection.
Antagonist Patent Pack
Download 805+ patent application PDFs
Antagonist Patent Applications
Download 805+ Antagonist-related PDFs
For professional research & prior art discovery
inventor
  • 805+ full patent PDF documents of Antagonist-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods and compositions for modulating the activity of the interleukin-35 receptor complex
St. Jude Children's Research Hospital
August 03, 2017 - N°20170218046

The receptor for interleukin 35 (il-35) is provided. The interleukin 35 receptor (il-35r) comprises a heterodimeric complex of the interluekin12rβ2 receptor and the gp130 receptor. Various compositions comprising the il-35r complex, along with polynucleotides encoding the same and kits and methods for the detection of the same the same are provided. Methods of modulating the activity of ...
Wnt antagonists and methods of treatment and screening
Oncomed Pharmaceuticals, Inc.
August 03, 2017 - N°20170218041

The present invention relates to compositions comprising wnt antagonists and methods of treating wnt-associated diseases and disorders, such as cancer, inducing differentiation, and reducing the frequency of cancer stem cells, as well as novel methods of screening for such wnt antagonists. In particular, the invention discloses soluble fzd, sfrp and ror receptors and their use.
N-terminally truncated interleukin-38
Fraunhofer-gesellschaft Zur FÖrdeung Angewandten Forschung E.v.
August 03, 2017 - N°20170218039

The present invention pertains to an n-terminally truncated interleukin (il)-38 protein, or functional variants thereof, as well as to nucleic acids and vectors encoding the truncated il-38 peptide and recombinant cells comprising these nucleic acids or vectors. The invention shows that il-38 is n-terminally processed and that the truncated version of the cytokine acts as an antagonist of immune ...
Ethynyl derivatives
Hoffmann-la Roche Inc.
August 03, 2017 - N°20170217926

The present invention relates to ethynyl derivatives as metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of, e. G., anxiety and pain, depression, fragile-x syndrome, autism spectrum disorders, parkinson's disease, and gastroesophageal reflux disease (gerd).
Compositions and methods for treatment of sickle cell disease
Biogen, Inc.
August 03, 2017 - N°20170216434

This invention relates to methods of treating sickle cell disease with vla-4 antagonists and methods for evaluating the responsiveness of patients having sickle cell disease to treatment with vla-4 antagonists.
Combination therapies and methods of use thereof for treating cancer
Massachusetts Institute Of Technology
August 03, 2017 - N°20170216317

Pharmaceutical compositions including an effective amount of an antiandrogen or androgen antagonist in combination with a plk inhibitor and methods of use thereof for treating cancer are disclosed. Administration of the combination of the active agents can be effective to reduce cancer cell proliferation or viability in a subject with cancer to the same degree, or a greater degree than ...
Ccr9 antagonist compounds
Merck Sharp & Dohme Corp.
August 03, 2017 - N°20170216295

Provided herein are compounds that inhibit ccr9 receptor function. Also provided herein are methods of treating inflammatory disease in a subject, comprising administering to the subject a compound of the invention. Accordingly, in one aspect, provided herein is a compound of formula (1) or a pharmaceutically acceptable salt thereof. In another aspect, provided herein is a pharmaceutical composition, comprising a compound ...
Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol ...
Merch Sharp & Dohme Corp.
August 03, 2017 - N°20170216250

Use of a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor for the treatment of diabetes and related conditions is disclosed.
Loading